← SynDRA
ATRASENTAN
SynDRA canonical compound SYN0000339 — structure-anchored drug synonym record
| Clinical phase | Phase 3 |
|---|
| Primary target(s) | EDNRA |
|---|
| Mechanism of action | Endothelin receptor antagonist |
|---|
All known targets
Mechanisms of action (all sources)
- Endothelin receptor antagonist
- EDNRA ANTAGONIST
- Endothelin receptor ET-A antagonist
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- CP2C9
- CP2D6
- CP3A7
- KSYK
- SYK
Drug classes
- Antineoplastic Agents
- Endothelin A Receptor Antagonists
Cross-references
Synonyms
- VANRAFIA
- Vanrafia
- Xinlay
- Atrasentan [INN]
- A-127722
- A-147627
- ABT-627
- Xinlay (TN)
- A-127722.5
- (+)-A-127722
- (11C)ABT-627
- A 127722
- V6D7VK2215
- ABT627
- A127722
- atrasentanum
- RefChem:115499
- A 127722.5
- DTXCID601509695
- A147627
- A127722.5
- UNII-V6D7VK2215
- ABT 147627
- ATRASENTAN [MI]
- P6FLG98GBJ
- ATRASENTAN [VANDF]
- ATRASENTAN [WHO-DD]
- SCHEMBL34654
- ABT-627;(+)-A 127722;A-147627
- GTPL3487
- orb1296093
- SERT inhibitor compound 8090
- SCHEMBL29361546
- CHEBI:135810
- MOTJMGVDPWRKOC-QPVYNBJUSA-N
- EX-A7929
- BDBM50051007
- EX-A14531
Look up ATRASENTAN in the interactive SynDRA portal →